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Background: The purpose of this investigation was to determine if black tea extract (BTE), consisting primarily of
flavanol compounds called theaflavins, could inhibit herpes simplex virus type-1 (HSV-1) infection in cultured A549
(human epithelial) and Vero cells.
Methods: The effect of BTE both on A549 and Vero cultured cells and on HSV-1 was assessed by using phase
contrast and fluorescent microscopy, and cell viability and proliferation assays. After establishing the maximum
non-cytotoxic concentration of BTE, A549 and Vero cells and HSV-1 virions were treated with varying concentrations
of BTE, respectively. A549 and Vero cells were infected with HSV-1 with green fluorescent protein (GFP) insert at the
UL46 gene. The effect of infectivity was determined by viral DNA extraction followed by PCR, plaque assays,
adsorption assays, and electrophoresis of PCR products.
Results: BTE was not cytotoxic to A549 and Vero cells, as confirmed by cell viability and proliferation assays, in
which BTE treated groups paralleled the positive control group. For both cell lines, plaque assays and fluorescent
microscopy indicated an inverse relationship between BTE concentration (from 0.14 μM – 1.4 mM) and HSV-1
infectivity. Specifically, PCR and electrophoresis showed a reduction in the viral genome following treatment with
BTE. In addition, there was a noticeable decrease in the amount of viral plaques for BTE treated samples in the
adsorption assays.
Conclusions: BTE consisting primarily of theaflavins is not cytotoxic and can reduce or block the production of
infectious HSV-1 virions in cultured A549 and Vero cells, thus inhibiting the infectivity of the virus by interfering in
the attachment, penetration and viral DNA replication of HSV-1 particles. These findings indicate that BTE enriched
with theaflavins has the potential to be developed as a safe, therapeutic antiviral agent to prevent the spread of
HSV-1.
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Herpes simplex virus type-1 (HSV-1) virions consist of
an inner core with linear, double-stranded DNA that is
enclosed in a capsid; an outer envelope containing vari-
ous glycoproteins covers tegument proteins, which are
exterior to the viral capsid [1,2].
The lytic infection cycle of HSV-1 begins with adsorp-
tion: when the virion first attaches to, then fuses with a
host cell. Both attachment and penetration take place
when viral glycoproteins bind to suitable receptors on the
plasma membrane of the host cell. The presence of the* Correspondence: adamssa@mail.montclair.edu
Department of Biology and Molecular Biology, Montclair State University,
Montclair, NJ 07043, USA
© 2013 Cantatore et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orreceptors determines the tropism of HSV-1 and places a
limit on the types of cells to which it is capable of
attaching, and thus, infecting [3-5]. Green, oolong, and
black teas are produced from the same plant, Camellia
sinensis. While the main type of flavanol in green tea
extract is the catechin, that in BTE is the theaflavin, a
dimer of different catechins, which includes: theaflavin
(TF-1), theaflavin-3-monogallate (TF-2A), theaflavin-3'-
monogallate (TF-2B) and theaflavin-3,3'-digallate (TF-3)
[6,7]. Since green tea is not fermented, it contains a rela-
tively high amount of catechins as compared to black tea;
fermentation causes the catechins to polymerize, which
produces the theaflavins and thearubigens found in black
tea, but absent in green tea [6].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dant properties, which in turn have been ascribed to cat-
echins, since green tea extract has been found to have
more antioxidant activity than black tea extract [7].
However, recent studies have shown that concentrated
theaflavin extracts made from black tea can be just as ef-
fective as catechins; it is believed that the high number
of hydroxyl (OH) groups of theaflavins, which have been
shown to protect cells against oxidative damage, is
responsible for its antioxidative properties [8,9]. Add-
itionally, it has been found that theaflavins are capable
of inhibiting certain types of cancer [10], as well as
inhibiting viruses, including bovine rotavirus and bovine
coronavirus [11], HIV-1 [12,13], and three different sub-
types of influenza strains [14].
While it has been shown that HSV-1 can be inhibited
by compounds in green tea extract and a variety of other
polyphenolic compounds [15], the purpose of this study
was to determine if black tea extract with a concentrated
amount of theaflavins (≥ 80%) (BTE) could also inhibit
HSV-1. Since theaflavins in BTE are composed of a
dimer structure formed from catechin monomers found
in green tea, which have been found to inhibit HSV-1
[15], it is reasonable to infer that theaflavins in BTE may
also produce similar results based on structural similar-
ities. Despite the fact that theaflavin molecules are larger
than catechins, larger polyphenolic compounds such as
tannins have been shown to inhibit other viruses [16,17],
indicating that the size of the molecule may not neces-
sarily be a factor required for viral inhibition. Rather, the
large amount of hydroxyl groups on these polyphenolic
compounds seem to be the one common structural
component among these various, natural viral inhibitors;
thus, BTE, with high concentrations of theaflavins, may
be an effective inhibitor of HSV-1.
Methods
Cells
Human epithelial (A549) cells [American Type Culture
Collection (ATCC), Manassas, VA, USA] were cultured
until confluent in 1X Ham's F-12K nutrient media,
Kaighn's modification with 2 mM L-glutamine, supple-
mented to contain 10% fetal bovine serum (FBS)
(Biowest, Miami, FL, USA) and 1 μg/mL gentamicin at
37°C and 5% CO2.
Vero cells [ATCC (Manassas, VA)] were cultured until
confluent in Dulbecco Modified Eagle Medium (DMEM)
with 5% FBS and 1μg/mL gentamicin at 37°C and 5% CO2.
HSV-1 UL-46 virus maintenance
A recombinant strain of HSV-1, GHSV-UL46, which
contains the sequence for green fluorescent protein
(GFP) fused to the tegument protein pUL46, was used
for all experiments [18] (ATCC, Manassas, VA, USA).Passage of virus was performed in T-25 flasks and cells
were allowed to reach complete cytopathic effect (CPE).
The media was then collected, centrifuged, and the super-
natant containing virus kept in cryogenic vials at −80°C.
Preparation of black Tea extract (BTE)
Black tea extract ≥ 80% theaflavins (BTE) (10 mg) (Sigma-
Aldrich, Saint Louis, MO, USA) was dissolved in 1 mL of
10% FBS-media to produce a stock concentration of 14 mM
BTE solution. Ten-fold dilutions (1.4 mM – 0.014 nM)
of stock were stored in microcentrifuge tubes at 4°C.
BTE cytotoxicity
Observation of cell morphology
Cell morphology was assessed using an Accu-Scope
3002 microscope by comparing treated and untreated
samples. A549 and Vero cells were plated in 6-well
plates, grown for 24 h, and then different concentrations
of BTE (14 mM to 0.014 nM) were added to the wells.
After 1 h the BTE was removed by aspiration and the
cells were washed with PBS. Fresh media was added to
the wells, and cells were examined at 400X for morpho-
logical changes after an additional 48 hour incubation at
37° and 5% CO2.
Cell viability assays
A549 and Vero cells were plated in 6-well plates, and
after 24 hours, different concentrations of BTE were
added to each well. After one hour, the BTE was aspi-
rated and the cells were washed with PBS, and cells,
including control groups, were incubated with media for
24 hours at 37° and 5% CO2. Cells were then stained
with trypan blue and counted using a hemocytometer.
Cell proliferation assay
A549 and Vero cell suspensions (100 μL) were
transferred to separate wells of a 96-well plate. To each
well that contained a sample, 10 μL of cell proliferation
reagent WST-1 (Roche Diagnostics, Indianapolis, IN,
USA) was added; the plate was gently rocked, then placed
in an incubator at 37°C and 5% CO2 for 30 minutes. The
absorbance level for each well was measured at 450 nm
in a microplate reader.
Viral inhibition
Virus inactivation assay
100 μL of BTE solutions were mixed with 100 μL of
HSV-1 in microcentrifuge tubes and incubated at 37°C
and 5% CO2 for 1 hour. Then, 200 μL of each mixture
was added to a separate well on a 6-well plate containing
Vero cells, from which the media had been aspirated.
The plates were incubated at 37°C and 5% CO2 for
1 hour and rocked every 15 minutes. After 1 hour, any
unabsorbed virus was aspirated and 2.5 mL of 5%
Cantatore et al. BMC Complementary and Alternative Medicine 2013, 13:139 Page 3 of 10
http://www.biomedcentral.com/1472-6882/13/139FBS-media was added to each well of Vero cells, and
incubated at 37°C and 5% CO2 for 48 hours; then media
from each well was harvested and used to infect fresh
monolayers of Vero cells (70 - 80% confluent). Plates
were incubated for 48 hours at 37°C and 5% CO2 and
monitored for cytopathic effect. Virus titers were deter-
mined by plaque assays.
Cell-treated extracts
A549 and Vero cells were plated in 6-well plates with
2.5 mL of cell suspension added to each well and incu-
bated at 37°C and 5% CO2 until 80% confluent. The
media was aspirated, and cells in each well were treated
with 100 μL of one of the 10 concentrations of BTE so-
lution. Plates were rocked and kept in an incubator at
37°C and 5% CO2 for 15 minutes. Unabsorbed solution
was aspirated and 100 μL of virus was added to each
well. The cells were incubated at 37°C and 5% CO2 for
1 hour and rocked every 15 minutes. After 1 hour, any
unabsorbed virus was aspirated and 2.5 mL of 10% FBS-
media was added to each well. The plates were incu-
bated at 37°C and 5% CO2 for 48 hours, then media
from each well was harvested and stored at −80°C.
Virus-treated extracts
To obtain media with virions from Vero and A549 cells
that had been infected with virus particles treated with
BTE solutions, 100 μL of undiluted HSV-1 was mixed
with 100 μL of BTE solution in a microcentrifuge tube
for each of the 10 concentrations of BTE solution. The
mixtures remained at room temperature for 15 minutes.
Then, 200 μL of each mixture was added to a separate
well on a 6-well plate containing A549 and Vero cells,
respectively, from which the media had been aspirated.
The plates were incubated at 37°C and 5% CO2 for
1 hour and rocked every 15 minutes. After 1 hour, any
unabsorbed virus was aspirated and 2.5 mL of 10% FBS-
media was added to each well of A549 cells, and incu-
bated at 37°C and 5% CO2 for 48 hours, then media
from each well was harvested and stored at −80°C.
Viral titer determination using plaque assay
Ten-fold serial dilutions of cell-treated and virus-treated
extracts of HSV-1 were prepared prior to infection.
Confluent A549 and Vero cell monolayers were then
infected with different dilutions of 100 μL HSV-1 and
allowed to adsorb for 1 hour at 37 °C and 5% CO2.
Unabsorbed viruses were aspirated, and plates were then
overlaid with a nutrient medium-containing agar and
incubated at 37°C and 5% CO2 for 3 days. Plaques were
visualized by staining cells with crystal violet and
counting within 50 hours. The plaque assay was carried
out in triplicate.Plaque reduction assay
Experimental wells of 6-well plates containing confluent
monolayers of A549 and Vero cells were infected with
virus suspensions to produce 20–30 plaques per well.
After 1 h incubation at 37 °C and 5% CO2, unabsorbed
virions were aspirated. BTE solution (1.4 mM, 0.14 mM,
14 μM, and 0.14 μM, respectively) was then added to
the appropriate wells, followed by nutrient medium-
containing agar; the plates were incubated at 37°C and 5%
CO2 for 3 days. Plaques were counted as described above.
Virus adsorption assay
Equal volumes (100 μL) of BTE solution and a virus sus-
pension, containing virus to yield 20–30 plaques per
well, were placed in microcentrifuge tubes, and the mix-
tures were incubated at 37°C for 1 h. The samples were
then placed on monolayers of A549 and Vero cells in
6-well plates and the virus was allowed to adsorb in the
presence of the extract. Unabsorbed solutions were aspi-
rated, and nutrient medium-containing agar was then
added to each of the wells, and the plates were incubated
at 37°C and 5% CO2 for 3 days. Adsorption efficiency
was assessed by counting plaques, as described above.
Virus attachment assay
BTE solution was added to wells of 6-well plates
containing monolayers of A549 and Vero cells, and the
plates were incubated at 4°C for 1 h. Extract solutions
were then removed and virus suspensions containing virus
to yield 20–30 plaques per well were added to each of the
wells. Plates were incubated at 4°C for 2 h to allow attach-
ment, then monolayers were rinsed 3 times with cold PBS;
unabsorbed solutions were aspirated. Nutrient medium-
containing agar was then added to each of the wells and
the plates were incubated at 37°C and 5% CO2 for 3 days.
Plaques were counted as described above.
Virus penetration assay
Virus suspensions were prepared on ice to produce
20–30 plaques per well on monolayers of A549 and
Vero cells in 6-well plates. Virus suspensions were
placed on cells, and plates were incubated at 4°C for 2 h
to allow attachment. BTE solution was then added to
the wells at room temperature and plates were incubated
at 37°C for 10 minutes to allow penetration. Unattached
virions were then washed off with PBS (pH = 3), and
unabsorbed solutions were aspirated. Nutrient medium-
containing agar was then added to each of the wells and
the plates were incubated at 37°C and 5% CO2 for
3 days. Plaques were counted as described above.
Fluorescent microscopy
To visualize the effect that the BTE solution had on viral
propagation, A549 and Vero cells were plated in 6-well
Table 1 The sequence, Tm and amplicon size of the designed primers used in PCR
Primers Target genes Nucleotide sequence (5′ to 3′) Tm (°C) Amplicon (nt)
gD1F HSV-1 US6 AGACGTCCGGAAACAACCCTACAA 64.6 752
gD1R ACACAATTCCGCAAATGACCAGGG 64.6
GFPF HSV-1 GFP TGACCCTGAAGTTCATCTGCACCA 64.6 717
GFPR AACTCCAGCAGGACCATGTGAT 62.7
VP1F HSV-1 UL46 ACCAAGCCTTGATGCTCAACTCCA 64.6 957
VP1R ACAACACGGTTCCCGAGAGTTTGA 64.6
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100 μL of BTE solution in a microcentrifuge tube. The
mixtures remained at room temperature for 15 minutes.
Then, 200 μL of each mixture was added to a separate
well on a 6-well plate that contained confluent cells. The
cells were incubated at 37°C and 5% CO2 for 1 hour and
rocked every 15 minutes. Any unabsorbed solution was
aspirated from the cells and 2.5 mL of FBS-media was
added to each well. The plates were incubated at 37°C
and 5% CO2. Cells were observed with a fluorescent
microscope, at 400X magnification every 6 hours post-
infection for 24 hours.
DNA extraction and quantification
DNA was extracted from infected A549 and Vero cells
that contained either 10% FBS-media or 5% FBS-media,
respectively or equal volumes HSV-1 virus treated in a
microcentrifuge tube with either 1.4 mM BTE solution
or 10% FBS-media (A549 cells), or one of the following
HSV-1/BTE lysates: 0.14 mM, 14 μM, 1.4 μM, and
0.14 μM concentrations (Vero cells). Cells were incu-
bated for 12 hours at 37°C and 5% CO2. The DNA from






















Figure 1 Trypan blue assay results for BTE cytotoxicity in A549 cells.
the total number of cells for each sample (an average of three separate samQiagen DNeasy® Blood & Tissue Kit (Qiagen Sciences,
Germantown, MD, USA), following the manufacturer’s
protocol. To quantify the total amount of DNA in both
the extracted DNA and PCR products, a NanoDrop
ND-1000 Spectrophotometer with accompanying com-
puter software (NanoDrop Technologies Incorporated,
Wilmington, DE, USA) was utilized, following the manu-
facturer’s protocol.
Primer design and polymerase chain reaction (PCR)
amplification of viral genes
Three sets of primers were designed to prime different
regions of the HSV-1 genome based on published se-
quences: HSV-1 US6 (encoding glycoprotein D), HSV-1
GFP [19], and HSV-1 UL46 (encoding VP11/VP12)
genes. The sequence, melting temperature (Tm) and size
of amplicons of forward and reverse primers are listed in
Table 1. DNA (100 ng) extracted from treated HSV-1
infected Vero and A549 cells was added to each PCR
reaction. Standard PCR amplification was performed in
25 μL reactions with an initial denaturation at 95°C for
2 minutes followed by 30 cycles of denaturation at 95°C
for 30 seconds, annealing at 60°C for 1 minute andoncentration
Results indicate the percentage of live or viable cells as compared to


























Figure 2 WST-1 assay results for BTE cytotoxicity in A549 cells. Results indicate the absorbance level (an average of three separate samples
on the same plate), which relates to the amount of live or viable cells for each treated sample. A higher absorbance level indicates more living or
viable cells than a lower absorbance level. As a reference, media containing no live cells with WST-1 produced an absorbance level of 0.211 (data
not shown). Values represent ± SD.
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tension period at 72°C for 10 minutes. Confirmation of
the correct amplicon size was determined by 1% agarose
gel electrophoresis and ethidium bromide staining.Table 2 Viral titers obtained from HSV-1 infectedResults
Black tea extract concentrations up to 14 mM have no
significant effect on cell morphology
A549 and Vero cells were exposed to ten-fold dilutions
of BTE, from 14 mM to 0.014 nM. No significant
changes in morphology, as determined by phase contrast
microscopy, were observed at any tested concentration
of BTE in A549 cells (data not shown). However, slight
changes in morphology were observed for Vero cells at
the highest concentration (data not shown). Vero cells
appeared to tolerate 1-hour exposure to BTE up to
1.4 mM (data not shown).cultured cells treated with different BTE concentrations
BTE Concentration Viral Titer (PFU/mL)
0 mM 8.0 x 106 a
2.5 x 106 b
0.14 μM 4.6 x 105 c
1.4 μM 3.4 x 105 b
6.0 x 104 c
14 μM 3.0 x 105 b
1.6 x 104 c
1.4 mM 0 a
2.2 x 102 c
14 mM 0 a, c
a A549 cells b Vero cells c 1 hr treatmentBTE does not reduce cell viability
The cell viability was quantitatively determined by using
trypan blue and hemocytometer direct cell count to
detect the effect of BTE on A549 cells (Figure 1). The
viability of the BTE-treated cells was similar to the posi-
tive control group treated with 10% FBS-media. As the
concentration of BTE increased, the percentage of cell
death did not increase. The tested concentrations of
BTE, from 14 mM to 0.014 nM, did not appear to be
cytotoxic to A549 cells. One unexplained deviation from
the group was the 14 mM BTE, which had a significantly
higher percentage of live cells compared to any other
group; these results were comparable for Vero cells (datanot shown). This BTE concentration, therefore, was not
used in the inhibition studies.Cell proliferation and viability assay indicates that BTE is
not toxic to A549 and Vero cells
To confirm the findings established by the trypan blue
assay, an assay using WST-1 reagent was conducted. In
this assay, only live cells can reduce WST-1, which is
light red, to formazan, which is dark red; thus, the
higher absorbance level is indicated by a darker color,
which correlates to the number of living cells. Overall,
the findings with the WST-1 assay for both A549 cells
(Figure 2) and Vero cells (data not shown) paralleled
those found for the trypan blue assay.
A B C D
Figure 3 Microscopy (400X magnification) of A549 cells. Panel A: A549 cells inoculated with HSV-1 taken at 12 hours post-infection; Panel B:
A549 cells infected with HSV-1 treated with 1.4 mM BTE, taken 12 hours post-infection. Panel C: A549 cells inoculated with HSV-1, taken 24 hours
post-infection. Panel D: A549 cells infected with HSV-1 treated with 1.4 mM BTE, taken 24 hours post-infection. Upper panels: fluorescent image;
Lower panels: merged image of fluorescent and phase contrast images.
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To visually observe the cytopathic effect (CPE) that
HSV-1 had on A549 and Vero cells and to determine
if BTE could inhibit HSV-1, either by reducing or
preventing the observable CPE, treated and untreated
cells infected with HSV-1 were observed at 400X magni-
fication using phase contrast microscopy. Clear differ-
ences between each group were seen 12 hours and
24 hours post-infection (data not shown).
Plaque assays were conducted to test the effect of BTE
on HSV-1. Titers determined by plaque assays of viral
extracts in A549 and Vero cells are reported in Table 2.
Treatment with BTE resulted in significantly reduced
viral titers, as compared to untreated groups. TreatmentFigure 4 Fluorescent Microscopy (400X magnification) of Vero cells in
treated with 1.4 mM to 0.14 μM concentrations of BTE; Lower panel: Untreof virions with various concentrations of BTE for one
hour resulted in significantly reduced viral titers, as
compared to untreated virus.
Fluorescent microscopy confirms the effectiveness of BTE
in inhibiting HSV-1 propagation
To confirm the findings of phase contrast microcopy
and the plaque assay, fluorescent microscopy (400×) was
employed to visually examine progeny virions in cells
that were exposed to HSV-1 treated with 1.4 mM of
BTE. For A549 samples, at 12 hours post-infection, there
was a pronounced fluorescence from cells infected with
untreated HSV-1 (Figure 3A), yet no viral fluorescence
was detected from either the control (cells treated withfected with HSV-1 taken 36 h post-infection. Upper panel: HSV-1
ated HSV-1.
Table 3 Quantification of DNA from Infected A549 Cells
A549 Sample Total DNA (ng/μL)
Mock-Infected 240.7 ± 10.8
Untreated HSV-1 391.7 ± 4.0
BTE Treated HSV-1 278.2 ± 10.2
Values represent ± SD of the average of three samples (data not shown). The
concentration of BTE was 1.4 mM.
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with HSV-1 treated with BTE (Figure 3B). At 24 hours
post-infection, there was still a significant amount of
fluorescence from cells infected with untreated HSV-1
(Figure 3C), but only a small amount of fluorescence
from cells inoculated with HSV-1 treated with BTE
(Figure 3D). For Vero cells infected with untreated
HSV-1, there was a significant amount of fluorescence
36 hours post-infection; Vero cells infected with increas-
ingly higher concentrations of BTE showed decreasing
levels of fluorescence (Figure 4).A
B
Figure 5 Gel electrophoresis of PCR products. A. PCR products extracte
(columns 2–4) or untreated (columns 5–7). Column 1 contains the DNA lad
Columns 2 and 5, 3 and 6, 4 and 7 contain DNA amplified with primers for
electrophoresis of HSV-1 GFP PCR products extracted from HSV-1 infected
or 1.4 mM BTE (columns 3 – 5, respectively). Column 1 contains the DNA laPCR amplification of BTE-treated HSV-1 infected
A549 and Vero cells indicates that the replication of
viral genes for glycoprotein D, GFP, and VP11/12 is
reduced following treatment of HSV-1 with higher
concentrations of BTE.
To determine if treatment with BTE interfered with
the production of viral genomes, PCR was used to com-
pare the relative levels of total DNA produced by infec-
tion with BTE-treated and untreated HSV-1. There was
approximately a 75% reduction in the concentration of
DNA in cells following treatment with 1.4 mM BTE
(Table 3). Gel electrophoresis of the PCR products from
DNA (extracted from HSV-1 infected A549 cells)
resulted in visible bands on the gel corresponding to
viral genes for glycoprotein D (gD), GFP and pUL46,
apparent for untreated HSV-1 and HSV-1 treated with
1.4 mM BTE; however, the former had a higher intensity
than the latter (Figure 5A). Sequence-specific primers
were also used to amplify the viral DNA (extracted from
HSV-1 infected Vero cells) encoding viral GFP atd from HSV-1 infected A549 cells either treated with 1.4 mM BTE
der, with visible bands identified to the left in base pairs (bp).
the HSV-1 gD, GFP and pUL46 genes, respectively. B. Gel
Vero cells either untreated (column 2) or treated with 0.14 μM, 1.4 μM,
dder, with visible bands identified to the left in base pairs (bp).
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treated with varying concentrations of BTE (Figure 5B).
The intensity of viral DNA products obtained after
infection with untreated HSV-1 (column 2), was greater
than that of HSV-1 treated with 0.14 μM, 1.4 μM, or
0.14 mM BTE (columns 3 – 5). Subsequent experiments
focused on how higher concentrations of BTE affected
HSV-1 infectivity.
BTE inhibited viral adsorption in A549 and Vero cells
through the combined effects of preventing viral
attachment and penetration
To determine if treatment with BTE interfered with viral
adsorption in A549 and Vero cells, either in part or in
whole, four assays were performed and compared to an
untreated sample infected by HSV-1. In the plaque re-
duction assay a slight reduction in plaques was observed
in the BTE treated group (Figure 6A), possibly due to
the inhibitory effects of BTE previously mentioned. The
virus adsorption assay (Figure 6B) showed a reduced
number of plaques in the BTE treated sample, indicating
that some part of adsorption was affected. Two add-
itional assays were performed to further assess whichA                                             
C
Figure 6 Viral titer determination using plaque assays. A. Plaque reduc
exposed to media only, A549 cells exposed to HSV-1 and media and A549
before being treated with BTE. B. Virus adsorption assay results showing (fr
exposed to HSV-1 and media and A549 cells exposed to HSV-1 and BTE. A5
assay results showing (from left to right wells): A549 cells exposed to medi
exposed to HSV-1 and BTE. A549 cells were treated with BTE before being
to right wells): A549 cells exposed to media only, A549 cells exposed to HS
were exposed to HSV-1 to allow attachment, but not penetration; cells wer
penetrate the cells.aspect of viral adsorption was affected. The virus attach-
ment assay displayed a significant reduction in the plaques
formed in the BTE treated group (Figure 6C), while the
penetration assay showed a similar reduction in plaque
formation in the BTE treated group (Figure 6D).
Discussion
The leading consumed beverage worldwide, after water,
is tea. For over 50 centuries, tea has been recognized for
its medicinal uses as an herbal treatment of multiple
ailments that range from simple indigestion to athero-
sclerosis [7,19]. Theaflavins, polyphenols found mainly
in black teas, are natural antioxidants and viral inhibi-
tors. As such, black tea extracts may be useful in future
pharmaceutical developments [20].
One concern for human health is HSV-1. Infections
caused by this herpesvirus are estimated to affect any-
where from 45% - 98% of the world population, and up
to 40% of these infected individuals are subject to recur-
rent outbreaks that most often result in infectious le-
sions and ulcerations of the skin. While treatments, such
as the drug acyclovir, are in use today, most rely on the
presence of a viral protein, thymidine kinase, to inhibitB
D
tion assay results showing (from left to right wells): A549 cells
cells exposed to HSV-1 and BTE. A549 cells were exposed to HSV-1
om left to right wells): A549 cells exposed to media only, A549 cells
49 cells were exposed to HSV-1 treated with BTE. C. Virus attachment
a only, A549 cells exposed to HSV-1 and media and A549 cells
exposed to HSV-1. D. Virus penetration assay results showing (from left
V-1 and media and A549 cells exposed to HSV-1 and BTE. A549 cells
e subsequently treated with BTE, then the virus was allowed to
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are still infectious but do not respond to the available
medications. In addition, current treatments can have
detrimental side effects and often require frequent doses
that can be expensive [16,21,22]. Thus, alternative, lower
cost treatments to HSV-1 infections are necessary to
alleviate the symptoms of infected individuals.
Black tea extracts have previously been found to block
the production of free radicals and inhibit the growth of
cancerous cells, as well as exhibit cytotoxic effects
against immortalized cells [23]. The purpose of this
study was to assess the antiviral qualities of a black tea
extract and determine its lowest inhibitory concentration
against HSV-1. This hypothesis stems from the findings
that black tea compounds have been shown to inhibit
some viruses [11-14]. In addition, a green tea catechin,
EGCG, has already been shown to inhibit HSV-1 [15,24];
it is suggested that this compound binds to glycopro-
teins on the envelope of the virus, thereby preventing
viral entry into the host cell [24]. Since black tea
theaflavins are merely polymers of green tea catechins
[6], it is possible that the former may also inhibit HSV-1,
though through a different mechanism. In addition, the
flavanols in black tea may be more stable than those in
green tea. Although the stability of green tea catechins is
pH dependent, EGCG and EGC were less stable than EC
and ECG, regardless of pH [25]. Theaflavins, however,
were reported to be more stable at pH 7 than EGC and
EGCG [26]. The increased stability of theaflavins at neu-
tral pH could make these black tea compounds a more
feasible option for the design of an antiviral therapeutic
agent than EGCG.
Inhibition was measured visually, through observations
that utilized both phase contrast and fluorescent micros-
copy, as well as quantitatively, by determining viral titers
with the plaque assay method and viral DNA concentra-
tions with samples extracted from infected cells. Phase
contrast microscopy and plaque assays demonstrated
that BTE significantly inhibited the infectious cycle of
HSV-1, consistent with findings of previous studies
[11-14]. These experiments demonstrated that non-
cytotoxic concentrations of BTE can effectively inhibit
the infectious cycle of HSV-1 in cultured cells. Similarly,
treatment with BTE for one hour significantly reduced
viral titers but did not inactivate the virions. Fluorescent
microscopy revealed that treatment of HSV-1 virions
with higher concentrations of BTE interfered with the
infectious cycle of the virus in cultured A549 and Vero
cells. Specifically, PCR and gel electrophoresis indicated
that higher concentrations of viral DNA are produced in
untreated HSV-1 infections, as compared to lower viral
DNA concentrations from BTE-treated HSV-1. Also, a
direct relationship between the increased BTE concen-
tration and reduced intensity of samples containing viralGFP suggests that there is a significant reduction in viral
genome replication in BTE-treated HSV-1 infected A549
and Vero cell cultures. Additional plaque assays indi-
cated that both the attachment and penetration
processes of HSV-1 adsorption in A549 cells and Vero
cells are inhibited by BTE concentrations of 1.4 mM and
14 μM. Experimental results taken a whole indicate that
BTE at non-cytotoxic concentrations can inhibit viral
propagation by limiting the viral processes of replication
and adsorption.
It has been reported that treatment of HSV-1 with
TF-3 for 1 h completely inactivated the virus [27]. The
effect of treatment of HSV-1 with BTE for 1 h was dose
dependent. Our results indicate that the virus is not
inactivated following 1 h treatment with BTE; therefore,
the action of TF-3 alone may not explain the efficacy of
BTE. Treatment with 1.4 mM BTE caused a reduction
in the amount of HSV-1 genome synthesized 12 h after
infection at this concentration and a lower viral count.
BTE has been reported to lack cytotoxic effects on cul-
tured cells, consistent with our findings [10]. Therefore,
BTE concentrations up to 1.4 mM can be used to treat
cells infected by HSV-1 and study its inhibitory effects.
Data presented here indicate that BTE can be safely
applied to cells at the concentrations tested. The lower
cost of BTE, as compared to pure theaflavins, make it
attractive for consideration as a safe and effective as an
antiviral agent.
Conclusions
BTE, consisting primarily of theaflavins, at concentra-
tions of 0.14 μM and higher reduce or block the produc-
tion of infectious HSV-1 virions in cultured A549 and
Vero cells, thus inhibiting the infectivity of the virus by
interfering in the attachment and penetration, as well as
the DNA replication of HSV-1 particles. These findings
indicate that BTE enriched with theaflavins has the
potential to be developed as a safe therapeutic antiviral
agent to prevent the spread of HSV-1.
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